within Pharmacolibrary.Drugs.ATC.L;

model L01EE01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.72,
    Cl             = 0.0535,
    adminDuration  = 600,
    adminMass      = 0.002,
    adminCount     = 1,
    Vd             = 1.83,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.00031666666666666665,
    Tlag           = 3600
  );

  annotation(Documentation(
    info ="<html><body><p>Trametinib is an oral, selective MEK1 and MEK2 inhibitor used primarily in the treatment of unresectable or metastatic melanoma with BRAF V600E or V600K mutations. It is approved for use, often in combination with dabrafenib, and is indicated for adult patients. It helps to inhibit the mitogen-activated protein kinase (MAPK) pathway, thereby reducing tumor cell proliferation.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in adult patients with solid tumors and metastatic melanoma administered trametinib orally.</p><h4>References</h4><ol><li><p>Leonowens, C, et al., &amp; Ouellet, D (2014). Concomitant oral and intravenous pharmacokinetics of trametinib, a MEK inhibitor, in subjects with solid tumours. <i>British journal of clinical pharmacology</i> 78(3) 524–532. DOI:<a href=&quot;https://doi.org/10.1111/bcp.12373&quot;>10.1111/bcp.12373</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24606567/&quot;>https://pubmed.ncbi.nlm.nih.gov/24606567</a></p></li><li><p>Flaherty, KT, et al., &amp; Weber, J (2012). Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. <i>The New England journal of medicine</i> 367(18) 1694–1703. DOI:<a href=&quot;https://doi.org/10.1056/NEJMoa1210093&quot;>10.1056/NEJMoa1210093</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23020132/&quot;>https://pubmed.ncbi.nlm.nih.gov/23020132</a></p></li><li><p>Ravix, A, et al., &amp; Guidi, M (2024). Population Pharmacokinetics of Trametinib and Impact of Nonadherence on Drug Exposure in Oncology Patients as Part of the Optimizing Oral Targeted Anticancer Therapies Study. <i>Cancers</i> 16(12) –. DOI:<a href=&quot;https://doi.org/10.3390/cancers16122193&quot;>10.3390/cancers16122193</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38927898/&quot;>https://pubmed.ncbi.nlm.nih.gov/38927898</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L01EE01;
